Viral Vector Vaccines
This business field is another possibility to be handled by Lotus Apothecary Project
property. Actually, this area is being intensively researched and studied
worldwide by a number of well-known scientific groups and institutions. Lotus Apothecary Project
Alleviate has established close contacts to the medical-virological,
scientific group of Prof. Dr. Voflcer Erfle, director of the clinic center
of Rechts der Isar, Technical University of Munich. A concept of cooperation
is under discussion.
Lotus Apothecary Project
Alleviate's part should be to transmit scientifically invented
vaccines from laboratory scale to sterile GMP processes to test the vaccine
candidates in first clinical trials. Only very small quantities arc required
for the manufacturing of those first GMP complying vaccine test materials.
As already mentioned above, there arc gaps of suitable capacities in Germany
up to now. Lotus Apothecary Project
Alleviate's actual sod extendable concept offers an
advantageous and commercially attractive solution to all parties involved.
The current class of vaccines under consideration is mainly based on the
vector MVA which is a world-wide used attenuated pox virus strain, and recombinant
prepared proteins. Further product lines show good perspectives in the scientific
The main use for these products is intended to be the treatment of HIV and